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Regarding “Endovascular versus surgical treatment
for thrombosed hemodialysis: a prospective,
randomized study”
To the Editors:
The recent article by Dougherty et al (J Vasc Surg
1999;30:1016-23) revisits several issues regarding throm-
bosed hemodialysis grafts. A flawed study design, insuffi-
cient information on the endovascular techniques used,
and an incomplete cost analysis limit the applicability of
the conclusions.
The study design lacks blinding. Despite randomiza-
tion of the patients, there is potential for outcome bias
when the same investigator performs both procedures.
Deliverers of the therapies that are being directly com-
pared for efficacy need to be blinded to the ongoing
results of the study to ensure scientific integrity and pre-
vent outcome bias.
The current endovascular technique for treatment of
thrombosed hemodialysis grafts is mechanical catheter
therapy. Urokinase is no longer commercially available
because the Food and Drug Administration detected a
number of problems regarding the processing and manu-
facturing of this drug.1 Mechanical catheter therapy has
been validated against both thrombolytic therapy and sur-
gical therapy. In comparison with thrombolytic therapy,
mechanical thrombectomy required less procedure time
(75 minutes vs 89 minutes, P < .04) with equivalent 3-
month patency as reported by Trerotola et al in 1998.2
According to Uflacker et al in 1996,3 mechanical therapy
was similar in initial technical success, primary patency,
and secondary patency to surgical thrombectomy.
Another point is the question of central venous steno-
sis as a cause for graft failure. Marston et al4 recently
reported central venous stenosis as a cause of graft failure
in 15% of patients. In the interventional radiology suite,
the central veins are routinely studied, and undergo fistu-
lography. In this paper there is no mention of central
venous evaluation. The cause of graft failure was not iden-
tified in seven (9%) of 80 patients. It is possible that cen-
tral venous stenosis was missed causing graft rethrombo-
sis. The information gathered by central venography is
also useful in planning further graft placement.4
The authors fail to report the type of endovascular
equipment used. How often was a second balloon needed?
Furthermore, the average amount of urokinase used per
patient is not reported. Urokinase is supplied in vials con-
taining 250,000 units. How often was a second vial need-
ed? Only rarely is more than one vial needed.
The cost analysis in this study as justification for use of
surgical thrombectomy over endovascular therapy is prob-
lematic. Dougherty et al report longer procedure times and
increased cost for endovascular therapy. However, Marston
et al4 reported equivalent costs between pulse-spray throm-
bolysis and surgical thrombectomy. Total procedure time is
variable and dependent on the expertise of the physician,
the complexity of the hemodialysis graft, and the venous
lesion to be treated. Most endovascular therapy is per-
formed in the radiology department, and therefore, a valid
cost comparison compels the investigators to use radiology
costs versus operating room costs. We speculate that the
reported increased cost and time of the endovascular proce-
dures may be operator dependent, institutional dependent,
and device dependent. Furthermore, the large number of
patients crossed over into the surgical thrombectomy arm
from the endovascular arm may represent the technical bias
of the investigators when faced with a complicated lesion.
The real issue is the optimization of patient care. This
is best achieved with a complementary approach between
the two therapies, each of which has its strengths and
weaknesses. A combined multimodality approach is need-
ed with refined algorithms to select the patients with the
appropriate indications who will most benefit from the
chosen therapy. Thus, multispecialty coordination among
nephrologists, vascular surgeons, and interventional radi-
ologists is needed to enhance patient care.5
Michael C. Farner, MD
Department of Radiology
Hospital of the University of Pennsylvania
Philadelphia, Pa
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Drs Farner and Sehgal raise several criticisms of our
study. With regard to “blinding,” this generally refers to
the evaluator of outcome being blinded to the treatment
group of a patient, which is impracticable (surgical
patients obviously have incisions) and unnecessary (the
primary end point of graft thrombosis is an objective
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event). We disagree with the contention that having the
same investigators perform both therapies biases results.
Vascular surgeons in our institution perform the full range
of endovascular interventions and have no intrinsic bias
against endovascular techniques.
With regard to mechanical thrombectomy devices,
Drs Farner and Sehgal state that these are “the current
endovascular techniques.” No doubt these devices are
being widely utilized, but there certainly have been no
prospective data validating this as the most efficacious
approach, and at a cost of approximately $600 per catheter
(substantially higher than urokinase cost) a cost advantage
should certainly not be inferred. In the cited randomized
study by Uflacker1 published in the radiology literature,
there is no life table patency analysis for this group of 37
patients. However primary patency at 30 days was only
47% for mechanical thrombectomy patients, compared
with 77% for surgical patients. In the study by Trerotola,2
which was a prospective analysis of the author’s propri-
etary device, over 60% of grafts had thrombosed within 90
days, results substantially worse than the endovascular arm
of our trial or the trial by Marston.3 With regard to the
question of materials utilized in endovascular treatment,
no artificial limits were set on the number of angioplasty
balloons that could be used, though rarely were more than
two catheters necessary. Only two patients had a second
infusion of 250,000 units of urokinase, and the cost of
urokinase and angioplasty balloons is reflected in the cost
analysis. Central veins were evaluated routinely with digi-
tal fistulography in the operating room setting. Indeed,
the two surgical crossovers were for balloon angioplasty of
subclavian vein lesions. Though central vein stenosis may
be a cause for inadequate dialysis and arm edema, it is
rarely a cause for graft thrombosis, and the 9% rate of
unexplained graft failure in our study is actually a lower
proportion than described in most series.
We disagree that comparing radiology department
costs with operating room costs is a more valid approach.
The fact that operating room time is typically charged by
the minute while angiography suite time is charged by pro-
cedure is an artifact of hospital accounting and billing tech-
niques rather than a measurement of actual resource uti-
lization. Indeed, surgeons could criticize the study in that
most do not perform fistulography, which clearly added to
the cost and time in the operative group; however, we felt
for a bona fide comparison of techniques, keeping treat-
ment protocols as similar as possible is preferred.
Although we concur with Drs Farner and Seghal that
the cost and time of the procedure will vary between oper-
ators and institutions, it is a little foolish to simply
acknowledge this and not attempt a prospective compari-
son for that reason. We disagree with the issue regarding
surgical crossover, as we stated in our discussion. Reported
rates of initial technical failure of 29% to 41% have been
published in the radiology literature, and the alternative
would have been to consider these patency failures.
Indeed, when these procedures are performed in the radi-
ology suite, increased costs are generated by the frequent
need for these patients to have a second procedure in the
operating room.
We do not disagree with the platitude that multiple
specialty involvement can be beneficial. However, this
does not obviate the need for prospective comparisons of
newer technologies with accepted standards.
Matthew J. Dougherty, MD
Department of Vascular Surgery
Philadelphia, Pa
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Regarding “Photoplethysmography and calf muscle
pump function after subfascial endoscopic perforator
ligation”
To the Editors: 
I read with interest the article of Illig and collaborators
from Rochester, NY, (J Vasc Surg 1999;30:1067-76)
because of the need of assessment of functional results
after a still controversial procedure in literature, the sub-
fascial endoscopic perforator interruption (SEPS). 
I agree that photoplethysmography (PPG) is an
imperfect method with possible overlaps in evaluating
venous function. On the other hand, venous function of
the lower limbs has proved to be a difficult entity to quan-
tify. Many other tests have been developed in an attempt
to separate normal from abnormal function, including
ambulatory venous pressure, foot volumetry, and air
plethysmography. Unfortunately, none of the above meth-
ods can completely categorize patients and limbs by clini-
cal severity of the disease. Despite this, PPG is an accept-
ed tool for measuring surgical results.1 Tracings like the
one reproduced at the bottom of Fig 2 do not represent
uninterpretable results; instead, they attest to an easily
interpretable inability of emptying of the venous system
after the procedure. This possibility has been well known
since the time in which such a procedure was performed
with an open technique.2,3
Elfstrom et al2 demonstrate by the means of strain-
gauge plethysmography that there was no increase in the
expelled volume after the surgical procedure. This is con-
firmed by the comparison between clinical and PPG
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